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The mechanism of cyclic AMP (cAMP) induction of fibronectin (FN) in HT-1080 and JEG-3 cells differs
(D. C. Dean, R. F. Newby, and S. Bourgeois, J. Cell Biol. 106:2159-2170, 1988). In the fibrosarcoma cell line
HT-1080, induction requires both protein synthesis and a lag period of 12 to 24 h. In the choriocarcinoma cell
line JEG-3, protein synthesis is not required and induction peaks before 24 h, declining thereafter. We show
that the FN promoter is transcribed in vitro and that the transcripts initiate at the proper site. Based on
transfection experiments with these cells and FN promoter constructions, a cAMP-responsive element (CRE)
was identified between -157 and -188 base pairs upstream of the human FN gene. This sequence also
conferred cAMP inducibility in both cell lines on the herpesvirus thymidine kinase promoter when it was placed
upstream of a thymidine kinase-chloramphenicol acetyltransferase fusion gene. DNase I protection analysis and
gel retardation experiments revealed that the CRE was bound by a protein(s) that was present in both HT-1080
and JEG-3 cells as well as in NIH 3T3 cells. Multiple protein-CRE complexes were resolved by gel retardation
with extracts of both cell lines. Forskolin treatment of these cells did not alter qualitatively or quantitatively the
pattern of CRE-binding proteins that was observed. The FN promoter was at least 10 times more active in
HT-1080 than in JEG-3 cells, even though in JEG-3 cells both the rate of FN biosynthesis and the level of
accumulated FN mRNA were greater than those in HT-1080 cells. The difference in promoter activity in
HT-1080 and JEG-3 cells was mediated by sequences that were located between positions -510 and -56.
Deletion of the FN promoter from positions -510 to -56 resulted in an -30-fold decrease in promoter activity
when this construction was transfected into HT-1080 cells, and similar results were observed in NIH 3T3 cells;
however, less than a 2-fold effect was observed in JEG-3 cells. Results of these studies suggest that there is some
degree of tissue specificity of FN gene expression and reveal that cAMP induction is mediated, in part, by the
same element (CRE) in both HT-1080 and JEG-3 cells.
Fibronectin (FN) is a large extracellular matrix glycopro-
tein which serves as a substrate for cellular adhesion. As
such, FN plays a role in cellular differentiation and migra-
tion, wound healing, hemostasis, and tumor metastasis (for
reviews, see references 1, 14, and 31).
We have recently demonstrated that the rate of transcrip-
tion of the FN gene is induced by cyclic AMP (cAMP) and
agents which increase intracellular cAMP levels (8). The
mechanism of this induction appears to be different in
different cell lines. In normal fibroblasts and in the chorio-
carcinoma cell line JEG-3, cAMP induction of FN mRNA
does not require protein synthesis and occurs rapidly, peak-
ing before 24 h and decreasing thereafter. In the fibrosar-
coma cell line HT-1080, cAMP induction of FN mRNA
requires both protein synthesis as well as a lag period of 12
to 24 h; approximately 48 h is required for full induction. The
amount of FN induction in HT-1080 (-27-fold) is also much
larger than that in normal fibroblasts or JEG-3 cells (-5-
fold). cAMP induction of FN expression is mediated by
5'-flanking sequences of the FN gene in HT-1080 and JEG-3
cells as well as in normal fibroblasts (8). It is of interest to
determine whether similar promoter elements and nuclear
proteins are required for this induction in cells in which there
are apparent differences in the mechanism of induction.
The sequence TGACGTCA, which is found at position
* Corresponding author.
-170 of the human FN gene (7), has been identified in the
cAMP-responsive element (CRE) of several genes (6, 9, 17,
24, 33). This sequence is necessary for cAMP induction but
requires surrounding sequences for activity (9, 24). A 43-
kilodalton nuclear protein binds to CRE, and its activity may
be modulated by phosphorylation (23). The CRE is similar in
sequence to the phorbol ester-inducible element (TRE) that
is found in several genes (1 base pair [bp] difference), but the
TRE is not responsive to cAMP (3, 16, 20, 21). The TRE is
the binding site of transcription factor AP-1 (activator pro-
tein 1) or c-jun (3, 21) and a c-fos protein complex (29). There
is evidence that AP-1 and c-jun, c-fos, the CRE-binding
protein (CREB), and the product of a recently isolated gene
junB (32) may belong to a family of related transcription
factors (2, 4, 32).
In this study we identified a CRE in the 5'-flanking region
of the human FN gene and demonstrated that this sequence
mediates cAMP induction in both HT-1080 and JEG-3 cells.
MATERIALS AND METHODS
Cell culture and DNA transfections. Cells were grown in
Dulbecco modified Eagle medium in the presence or absence
of 10% fetal bovine serum at 37°C as described previously
(8). The HT-1080 cell line (28) was subcloned, and a clone,
HT-1080C, was used in this study (26). JEG-3 cells (19) were
not subcloned. Cells were transfected by the calcium phos-
phate method described previously (8). As an internal con-
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trol, plasmid pRSV-pGal (11) was cotransfected with the test
plasmid DNA. The cells were incubated for 5 h in the
presence of the precipitated DNA and then rinsed two times
with phosphate-buffered saline to remove the calcium phos-
phate. Assays for P-galactosidase were done as described
previously (11) and were used to normalize the amount of
protein extract used for chloramphenicol acetyltransferase
(CAT) assays (13). JEG-3 cells were treated with forskolin
(1.8 x 10-5 M) for 24 h, and HT-1080 cells were treated for
40 h.
Plasmid constructions and DNA sequencing. The plasmid
pFNCAT contains DNA sequences from +69 to approxi-
mately -1.6 kilobases (kb) of the human FN gene fused to
the CAT gene (8). Deletions in the FN sequence were made
by using the following restriction enzyme sites: PvuII at
position -510, NaeI at position -122, and SmaI at position
-56. The same sites and a BstNI site at position -222 were
used to obtain the FN gene 5'-flanking fragments for place-
ment upstream of the thymidine kinase (TK) promoter. The
3' end of the FN promoter fragments corresponded to either
PstI (position +69) or NaeI (position +8) restriction sites.
For cloning into the HindlIl site of the TK-CAT plasmid (see
Fig. 5), both the HindIII site in the vector and the BstNI site
of the FN gene were blunt-ended with the Klenow fragment
of DNA polymerase I (22).
DNA sequencing was carried out on fragments that were
subcloned into the plasmid pGEM-4 (Promega Biotec). Di-
deoxy sequencing of supercoiled plasmids was done as
described by the suppliers (Promega Biotec, Madison, Wis.).
In vitro transcription assays. Nuclear extracts from HeLa
cells were prepared by the method of Dignam et al. (10).
Transcriptions were carried out in a 25-,I reaction volume
containing 15 ,ul of nuclear extract, 0.5 ,ug of template DNA,
and 100 ,uM each of ATP, CTP, and GTP, with 30 ,uM UTP,
5 ,uCi of [a-32P]UTP (600 Ci/mmol), and MgCl2 added as
indicated. Reactions were incubated for 30 min at 30°C in the
presence or absence of a-amanitin, after which time they
were terminated and processed as described previously (12).
Radiolabeled RNA was then fractionated by electrophoresis
in a 4% sequencing gel.
DNase I protection analysis. Nuclear extracts were pre-
pared from HT-1080 and JEG-3 cells as described previously
(25). Probes for DNase I protection were prepared from the
vector pGEM-4 (Promega Biotec) containing the FN pro-
moter sequence from positions +69 to -510 cloned between
the PstI (+69 end) and the SmaI (-510 end) sites of the
vector. The plasmid was digested with either EcoRI, which
was adjacent to the SmaI site, or with HindlIl, which was
adjacent to the PstI site. The linearized plasmid was then
labeled with 32P by using polynucleotide kinase (22). Plasmid
labeled at the EcoRI site (noncoding strand) was then cut
with Hindlll, and plasmid labeled at the HindlIl site (coding
strand) was digested with EcoRI. Labeled fragments were
purified on polyacrylamide gels and used for DNase I
protection assays as described previously (25).
Gel retardation assays. Gel retardation assays were done
as described by Treisman (36), but with several modifica-
tions. Nuclear extracts were prepared as described above for
the DNase I protection analysis. Extracts were incubated in
10% glycerol-25 mM Tris hydrochloride (pH 7.5)-100 mM
KCl-5 mM spermidine-5 mM EDTA-1 mM dithiothreitol-1
,ug of herring sperm DNA in 15-pA volumes with -0.5 ng of
32P-labeled oligonucleotide. Incubations were done for 30
min at room temperature, and the samples were loaded
directly onto a 4% polyacrylamide gel run at -4 V/cm. Gels
were dried and autoradiographed.
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FIG. 1. In vitro transcription of the human FN promoter. Tran-
scriptional assays were carried out with HeLa cell nuclear extracts
as described in the text. The plasmid pFNCAT (-510) was used as
the template DNA. The plasmid was digested with either PvuII
(position +227) or EcoRI (position +329), and the site of transcrip-
tional initiation of runoff transcripts was determined on a 4%
sequencing gel by comparing the mobilities of the bands with that of
a DNA sequence that was run in parallel. Lanes 1 to 4 (EcoRI),
experiments done in the presence of various concentrations of
MgCl2 (lane 1, 1 mM; lane 2, 5 mM; lane 3, 7.5 mM; lane 4, 11 mM);
lane 5 (PvuII), 5 mM MgCl2; lane 6, same as lane 2; lanes 7 and 8
(PvuII), 5 mM MgCI2, 0.5 and 200 pg of a-amanitin per ml,
respectively; lanes 9 and 10 (EcoRI), 5 mM MgCl2, 0.5 and 200 ,ug of
a-amanitin per ml, respectively. The arrows indicate correctly
initiated transcripts from EcoRI- and PvuII-cut plasmids.
RESULTS
In vitro transcription of the FN gene. The plasmid
pFNCAT (-510) containing residues from positions -510 to
+69 of the human FN gene fused to the CAT gene was
digested with either PvuII or EcoRI and incubated with
HeLa nuclear extracts for in vitro transcriptional runoff
experiments (Fig. 1). An optimal MgCI2 concentration of 5
mM was determined by titrating the amount of MgCl2 in the
reaction. Specific bands of 227 nucleotides (PvuII) and 329
nucleotides (EcoRI) were observed, indicating that in vitro
transcription of the FN promoter initiates at the in vivo cap
site. Each of these bands disappeared in the presence of low
concentrations of a-amanitin, indicating that they were
polymerase II transcripts.
Effect of the amount of FN promoter transfected on forsko-
lin induction. The amount of the plasmid pFNCAT (-510)
that was transfected into HT-1080 and JEG-3 cells was
varied, and the effect on forskolin inducibility was exam-
ined. Basal expression increased in a linear fashion in both
cell lines when the plasmid was increased; however, forsko-
lin inducibility decreased with the amount of plasmid added
in both cell lines (Fig. 2). In HT-1080 cells induction was
20-fold when 1 ,ug of plasmid was transfected and declined to
2.8-fold when 15 ,ug of plasmid was transfected. In JEG-3
cells induction was 12-fold with 3 ,ug of plasmid; this
declined to 2.6-fold with 20 ,g of plasmid. This suggests that
at least one of the factors that is important for forskolin
induction is present at a lower abundance or has a lower
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FIG. 2. Effect of FN-CAT copy number on forskolin induction.
The amount of pFNCAT (-510) transfected into both HT-1080 and
JEG-3 cells was varied. The total DNA was maintained at a constant
level (15 ,ug for HT-1080 and 20 jig for JEG-3) by the addition of the
plasmid vector pGEM-4. Forskolin was added at 1.8 x 10-5 M for 18
h in JEG-3 cells and 36 h in HT-1080 cells. Points were determined
by cutting spots from the chromatograms and counting the radioac-
tivity. The number of micrograms of DNA given corresponds to the
amount of pFN-CAT (-510) added. Symbols: *, Experiments done
in the presence of forskolin; O, experiments done in the absence of
forskolin. Numbers preceding the X represent the fold induction of
CAT activity in each experiment. These experiments were repeated
two times, with similar results obtained each time.
affinity than the factors that are necessary for basal expres-
sion of the FN gene.
The FN promoter is more active in HT-1080 than in JEG-3
cells. Cells were transfected with 5 p,g of FN-CAT plasmid
DNA. This amount of DNA allowed the detection of a
measurable basal level of expression and forskolin inducibil-
ity (Fig. 2). The FN promoter appeared to be at least -10
times more active in HT-1080 than in JEG-3 cells when FN
promoter activity was compared with the activity of the
simian virus 40 early promoter in each cell line (Fig. 3).
Similar results were obtained if FN promoter activity was
compared with the activity of either the Rous sarcoma virus
(RSV) long terminal repeat (pRSV-pGal) or the herpesvirus
TK promoter (TK-CAT) in both cell lines (data not shown).
This was of interest since the amount of FN protein and
mRNA was actually greater in JEG-3 cells. We have dem-
onstrated previously that the half-life of FN mRNA in
HT-1080 is shorter than that in normal fibroblasts (8).
Therefore, the apparent discrepancy in promoter activity
and FN levels may be due to a longer mRNA half-life in
JEG-3 cells compared with that in HT-1080 cells.
The difference in FN promoter activity in HT-1080 and
JEG-3 cells was mediated by sequences between positions
-56 and -510 (Fig. 3). Deletion of sequences between -1.6
kb and -510 bp resulted in an approximately threefold
increase in expression in both cell lines, suggesting that a
negative element may reside in this region. The FN promoter
(position -510) was 12.5 times more active in HT-1080 cells
than it was in JEG-3 cells. Deletion to -122 bp decreased
this difference to only fivefold, while deletion to -56 bp
resulted in equal activity in both cell lines. This indicates
that in JEG-3 cells there is very little effect of sequences
between -510 and -56 bp (<twofold) on transcription.
However, in HT-1080 cells there was a strong dependence
on this region. The region between positions -56 and -122
increased promoter activity 8.2-fold, while the whole region
between positions -56 and -510 increased activity 30-fold.
Similar effects were observed in NIH 3T3 cells (Fig. 4).
Differences in expression of the FN promoter in HT-1080
and NIH 3T3 cells compared with that in JEG-3 cells
reflected tissue specificity in the ability to respond to ele-
ments between positions -510 and -56.
Forskolin induction of the FN promoter. The FN promoter
was inducible by forskolin in HT-1080 and JEG-3 cells (Fig.
3) and in NIH 3T3 cells (Fig. 4). It is also demonstrated in
Fig. 4 that the FN promoter is induced by transforming
growth factor P, and by treatment of serum-starved cells
with serum in NIH 3T3 cells, suggesting that the regulation
of FN expression in these cells was similar to that demon-
strated previously for other cell lines (8). In HT-1080 cells
forskolin inducibility was eliminated on deletion to -122 bp
(Fig. 3). This eliminated the sequence TGACGTCA at posi-
tion -170 which we identified previously (7) and which is
similar to the core sequence of a CRE (6, 9, 17, 24, 33). In
JEG-3 cells the deletion at -122 bp eliminated a portion of
the forskolin induction; however, this construction was still
induced threefold. Deletion to -56 bp eliminated forskolin
induction in both cell lines. Examination of FN gene se-
quences between -122 and -56 bp revealed the sequence
5'-CCGCCCGCC-3' at -119 bp on the coding strand which
resembled the binding site for AP-2 of the metallothionein
gene (5'-CCGCCCGCG-3') that has been demonstrated to
mediate forskolin inducibility (15). DNase I protection was
observed in this region with extracts from JEG-3 cells but
not from HT-1080 cells (see Fig. 6).
Effect of various segments of the FN gene 5'-flanking region
on expression of the TK promoter. Various segments of the
FN gene 5'-flanking region were placed upstream of the TK
promoter (Fig. 5). The effect of these fragments on TK
expression was analyzed in the presence or absence of
forskolin (Fig. 5). A two- to fourfold increase in the basal
level of TK expression was observed with the various
fragments in each of the cell lines.
FN gene sequences between -122 and -510 bp were able
to confer forskolin inducibility on the TK promoter. Most of
this induction was eliminated when the region from -222 to
-510 bp was used. However, the region between -122 and
-222 bp was able to confer inducibility. A synthetic oligo-
nucleotide containing the sequence from positions -157 to
-188 was able to confer forskolin inducibility on the TK
promoter, indicating that this sequence is a CRE. All of the
FN segments shown in Fig. 5 were placed in the opposite
orientation with respect to their natural orientations in the
FN promoter. Similar results were obtained when the direct
orientation of several of the constructions in HT-1080 cells
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HT1 080 JEG-3
forskolin: - + +I + +
FN fragment
no promoter EG BG 8; 8
-1.6kb/+69bp 20 177 8.9 2.0 11 5.5
-51 Obp/+69bp 66 431 6.5 5.3 27 5.1
-122bp/+8bp 18 14 0.8 3.6 1 1 3.1
-56bp/+8bp 2.2 3.2 1.5 2.8 2.1 0.8
pSV2CAT 1000 1000
FIG. 3. Effect of successive 5' deletions on the activity and forskolin inducibility of the human FN promoter. A schematic diagram of the
constructions is shown at the top. The numbers in the left column represent the amount of FN 5'-flanking sequence in the plasmid. The
numbers representing CAT activity in the absence (-) or presence (+) of forskolin treatment were determined by counting spots from
chromatography plates and normalizing the values to the activity of the simian virus 40 early promoter (which was set to be equal to 1,000).
Each number is the average of three different experiments, and none of the values varied from the mean by more than 30%. The values
presented under the +/- columns represent induction ratios calculated by dividing the values obtained in the presence of forskolin (+) by
those obtained in the absence of the drug (-). BG, Not significantly above that of the background.
was used (positions -510 to -122 and positions -188 to
-157) (data not shown).
Analysis of protein-binding sites on the FN promoter in
vitro. Forskolin induction of the FN promoter was mediated
through a CRE at -170 bp in each of the cell lines. Since
-51OFNCAT ( ':
z zv
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FIG. 4. Effect of forskolin (F), transforming growth factor I
(TP), and serum treatment (S) and the effect of 5' deletions on
expression of the FN promoter after transfection into NIH 3T3 cells.
Serum-starved cells (no serum [NS]) were incubated for 36 h in the
absence of fetal bovine serum, while serum-treated cells were
incubated for 24 h in the absence of serum followed by treatment for
18 h with 10o fetal bovine serum. Treatment with forskolin was for
24 h, as described in the legend to Fig. 2, and T growth factor-PI1 (250
pM) treatment was for 18 h. Dishes (diameter, 10 cm) were trans-
fected with 5 p.g of the indicated FN promoter plasmid. Numbers in
front of FN-CAT indicate the length of the FN promoter fragments
in each construct: -1.6, 1.6 kb; -510, 510 bp; -122, 122 bp; and
-56, 56 bp. All experiments were done in the presence of 10%o fetal
bovine serum unless otherwise indicated.
protein synthesis is required for induction in HT-1080 cells
but not in JEG-3 cells (8), it was of interest to determine
whether the CREB was absent in untreated HT-1080 cells.
DNase I protection was used to detect the binding of nuclear
proteins to the FN promoter in vitro (Fig. 6). The region of
the FN promoter around the CRE at -170 bp was protected
with nuclear extracts from both HT-1080 and JEG-3 cells.
Protection was observed in both strands, and hypersensitive
sites were seen at the boundaries of the protected region. A
similar amount of nuclear extract from each cell line was
required for protection of the CRE, suggesting that CREB is
present at similar concentrations in the two cell lines. In the
case of HT-1080 nuclear extracts, DNase I protection in the
region of the CRE covered two separate elements. Immedi-
ately 3' of the CRE was what appeared to be a nuclear factor
1-binding site (position -155). Protection of the CRE was
eliminated on competition with an excess of an oligonucle-
otide containing the CRE, while protection of the putative
nuclear factor 1 site was unaffected (data not shown).
However, with nuclear extracts from JEG-3 cells, the CRE
footprint did not extend 3' of position -160. This could have
been caused by the absence of nuclear factor 1-binding
activity in JEG-3 cells, but this possibility was not examined.
One additional protected region was observed with extracts
of both cell lines at about position -420. There was evidence
for protected regions and hypersensitive sites in other re-
gions as well, in particular, in the region from positions -53
to -115 (best visible on the coding strand in Fig. 6). This
region was highly GC-rich and could correspond to several
binding sites for transcription factor Spl.
A gel retardation assay was done with an oligonucleotide
containing the CRE (see Fig. 5 legend for a description of
this oligonucleotide). Various amounts of extract from HT-
1080, JEG-3, and NIH 3T3 cells were tested (Fig. 7). Each
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-350 -109 +51
HT-1080 JEG-3 NIH 3T3
FN FORSKOLIN: - + +/- - + +/- - + +/-
no FN 26 19 0.7 16 13 0.8 37 31 0.8
-122/-510 71 496 7.0 26 196 7.5 92 505 5.5
-222/-510 56 92 1.6 3 1 74 2.3 nd nd
-1 22/-222 49 404 8.2 21 139 6.6 nd nd
-157/-188 44 338 7.7 26 156 6.0 49 308 6.3
pSV2CAT 1000 1000 1000
FIG. 5. Effect of segments of the FN gene 5'-flanking region on activity and forskolin inducibility of the TK promoter. A schematiL
diagram of the plasmids is shown at the top. FN DNA segments were cloned into the HindIll site of the TK-CAT plasmid at position -350
from the TK cap site (position +1). The numbers in the left column indicate the fragment of the FN gene 5'-flanking region present in each
plasmid. The fragment from positions -157 to -188 was a synthetic oligonucleotide which corresponded to that region of the FN gene
5'-flanking sequences. CAT activity was normalized to that of the simian virus 40 early promoter (which was equal to 1,000), and the values
obtained in the absence (-) or the presence (+) of forskolin and the induction ratios (+/-) were calculated as described in the legend to Fig.
3. This experiment was repeated at least five times. The values are averages of two experiments which were done at the same time and were
representative of the other experiments. Each of the values was within 25% of the mean.
cell line contained a factor(s) which bound the CRE. Multi-
ple complexes were seen with extracts from each cell line.
Competition assays with an excess of cold oligonucleotide
containing the CRE demonstrated that the binding was
specific (Fig. 7A). In addition, when a 10-fold excess of
competitor was used, two of the lower bands were still
present, suggesting that these bands may represent the
highest-affinity complexes; however, even these complexes
were not able to bind in the presence of a 100-fold excess of
competitor. Figure 7B shows a comparison of binding with
extracts from HT-1080 and JEG-3 cells and the effect of
forskolin treatment on binding. Multiple complexes were
observed with extracts from both cell lines, and the migra-
tion of several of these complexes was similar in the two cell
lines; however, there were at least two slowly migrating
bands which were present with JEG-3 extracts that were not
seen with HT-1080 extracts. There was also a rapidly mi-
grating band which was present with HT-1080 extracts but
not with JEG-3 extracts. There were no apparent differences
in the abundance or mobility of the complexes in extracts
from cells that were treated with forskolin. This was also
true with extracts from NIH 3T3 cells (data not shown).
Sequence comparison of the 5' end and 5'-flanking region of
the human and rat FN genes. The sequences of the 5' ends
and the 5'-flanking regions of the rat and human FN genes
are compared in Fig. 8. The two sequences were similar, and
many of the differences which did occur resulted from the
deletion or insertion of DNA segments. The CRE (position
-170) and its adjacent sequences were identical in the rat
and human FN genes. Immediately 3' of the CRE (centered
at about -155 bp) there appeared to be a nuclear factor
1-binding site (30) which was similar in both sequences
(CGGAN56GCCAAT). The other DNase I-protected re-
gions at -260 and -415 bp were also conserved in the two
species.
DISCUSSION
Properly initiated transcripts were observed from the FN
cap site when the FN-CAT fusion gene was used as a
template for in vitro transcription. This suggests that CAT
expression from the FN-CAT fusion gene is a reflection of
FN promoter activity.
The FN promoter appeared to be at least 10 times more
active in HT-1080 cells than in JEG-3 cells. This was
surprising, initially, since JEG-3 cells have a greater rate of
FN biosynthesis and a higher level of FN mRNA than do
HT-1080 cells (8). We have demonstrated previously that the
half-life of FN mRNA is shorter in HT-1080 cells than it is in
normal fibroblasts (8). Therefore, this apparent discrepancy
between promoter activity and the mRNA level in HT-1080
and JEG-3 cells probably results from a longer FN mRNA
half-life in JEG-3 than in HT-1080 cells; however, direct
measurements of the FN mRNA half-life have not been done
in JEG-3 cells.
Deletion of FN gene sequences from positions -510 to
-56 resulted in less than a 2-fold decrease of FN promoter
activity in JEG-3 cells, while a similar deletion in HT-1080 or
NIH 3T3 cells produced an -30-fold decrease. The promoter
activity in HT-1080 and JEG-3 cells was similar when the
gene was deleted to position -56. The ability of the FN
promoter to respond to sequences upstream of position -56
seemed to be tissue specific, since it was seen in both murine
fibroblasts (NIH 3T3) and a human fibrosarcoma cell line
(HT-1080) but not in a human choriocarcinoma cell line
(JEG-3).
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FIG. 6. DNase I protection assays of the human FN gene pro-
moter. A DNA fragment of the 5'-flanking region of the FN gene
from positions +69 to -510 was 32P labeled on the 5' end of one
strand 16 bp downstream of position +69 (HindIIl site in vector) and
was labeled on the other strand 18 bp upstream of position -510
(EcoRI site in vector). Labeled fragments were incubated in the
absence (-) or presence (+) of nuclear extracts from JEG-3 (400 ,ug)
or HT-1080 (200 ,ug) cells, treated with DNase I, and electro-
phoresed on 6% sequencing gels. Brackets indicate the boundaries
of the protected regions (expressed in nucleotides from the site of
initiation of transcription), which were calculated by using the
fragments of MspI-digested plasmid pBR322 as size markers (data
not shown). The arrows and the dashed bracket indicate various
regions with an altered DNase I sensitivity.
We have demonstrated previously that the mechanism of
cAMP induction of FN is different in the fibrosarcoma cell
line HT-1080 compared with that in the choriocarcinoma cell
line JEG-3 (8). In most cell lines tested, the rate of FN
biosynthesis is induced rapidly by cAMP or agents which
increase intracellular levels of cAMP. A peak is reached
before 24 h of treatment, and after this time expression
decreases (to a point below the uninduced level in some cell
lines). Inhibition of protein synthesis has no effect on the
induction of FN mRNA in JEG-3 cells. However, in HT-
1080 cells induction requires both a lag period of 12 to 24 h
and protein synthesis (8). In this study we showed that a
-F
FIG. 7. Gel retardation assays of binding to the CRE in extracts
from NIH 3T3, JEG-3, and HT-1080 cell lines; effect of forskolin
treatment. (A) Extracts from NIH 3T3 cells were incubated in the
presence of 32P-labeled double-stranded oligonucleotide, which con-
tained the CRE, and were subjected to electrophoresis on nondena-
turing polyacrylamide gels as described in the text. Lane 1, 25 ,ug of
extract in the presence of a 100-fold excess of unlabeled CRE; lane
2, 25 pg of extract from a 10-fold excess of unlabeled CRE; lane 3,
25 pg of extract; lane 4, 51 ,ug of extract; lane 5, no extract. (B)
Effect of forskolin treatment on binding to the CRE in extracts from
HT-1080 and JEG-3 cells. The reactions contained 5 (lane 1) and 25
(lane 2) ±g of protein extract. In lanes labeled with a plus sign, cells
were treated with forskolin (as described in the legend to Fig. 2)
before the extracts were made. Abbreviations: F, Uncomplexed
oligonucleotide; C, oligonucleotide complexed with nuclear factors.
CRE is present at position -170 of the human FN gene and
that this sequence can mediate cAMP induction in both
HT-1080 and JEG-3 cells. Thus, it seems likely that there is
a common pathway of cAMP induction in both cell types. In
addition, a second sequence between positions -56 and
-122 also contributes to cAMP induction in JEG-3 cells but
not in HT-1080 cells. This site seems to function indepen-
dently of the CRE. A sequence similar to the AP-2 site of the
metallothionein gene, which has been demonstrated to me-
diate cAMP induction (15), is found in this region. It is not
known, however, whether this is a functional AP-2-binding
site; however, this region was protected in DNaseI protec-
tion assays with extracts of JEG-3 cells but not with extracts
of HT-1080 cells. Since protein synthesis was required for
induction in HT-1080 cells, one or more of the protein
components of this pathway must be underrepresented in
these cells. This factor does not appear to be CREB itself,
since binding to the CRE was detected in both JEG-3 and
HT-1080 cells. Multiple protein-CRE complexes (four to five
bands) were observed with extracts from each of the cell
lines. Several of the complexes had different electrophoretic
mobilities when extracts from HT-1080 and JEG-3 cells were
compared. The significance of these differences is unknown.
Incubation of cells with forskolin before extracts were made
did not alter the complexes that were formed from either
cell. This indicates that the effect of forskolin is not to alter
the affinity of CREB for the CRE, suggesting that the
interaction of CREB with another transcription factor may
be of importance and that forskolin may act to mediate such
an interaction. However, we were not able to detect changes
in the CRE-CREB complex, i.e., binding of an additional
protein, when extracts from forskolin-treated cells were
used.
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-300
GCCA---CTCCCTTTCCTCC-----------------CAGCCGCTTCCCATCCCTTCCCCCA----TCCC
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-100
-50 '
GGGTCTCTCCTCCCCCGCGCCCCGGGCCTCCAGAGGGG-CGGGAGGGCC--GTCCCATATAAGCCCG-GC
-_____CTCCTCCCCGGCGCGCAGGGCCTCGTGGGGGGGCGGGAAGGGACTGTCCCATATAAGCCTCTGC
-50
+1 +50
TCCCGC-GCTCCGACGCCCGCGCCGGCTGTGCTGCACAGGGGGAGGAGAGGGAACCCCAGGCGCGAGCGG
TCTTGGGGCTCAGCCGCTCGCACCCGCTGCACTGCACAGGGGAAGAAAAG-GAGCCCAGGGTGTGAGCCG
I I I I I I
+1 +50
FIG. 8. Comparison of the 5' end and 5'-flanking regions of the human and rat FN genes. The human sequence to position -309 was from
Dean et al. (7). The remainder of the sequence is reported here for the first time. The rat sequence is from Patel et al. (27). The alignment
of the sequences was done with a software program (Intelligenetics IFIND) by using the align command. The parameters were as follows:
Gap penalty, 4; DNA window, 20. Arrows indicate the start sites of transcription. Boxes are drawn around sequences that were protected
in DNase I protection assays (Fig. 6). Bars are drawn over sequences which are similar to known regulatory elements.
It has been suggested that the activity of CREB is modu- factor would be, either directly or indirectly, inducible by
lated by phosphorylation (23). Therefore, it is possible that cAMP. It has been demonstrated that the presence of an
either the level of the kinase responsible for this phosphor- activated N-ras gene can inhibit the cAMP pathway (35).
ylation or a factor(s) that is involved in activation of this This suggests that in cells that are transformed by activated
kinase may be suppressed in HT-1080 cells. Such a kinase or ras genes, a group of genes which is normally induced by
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cAMP is not activated. Since HT-1080 cells contain an
activated N-ras gene (5), it is possible that the differences
observed in the mechanism of cAMP induction in HT-1080
and JEG-3 cells is due to the presence of this oncogene.
The effect of activated ras genes on cells seems to be
similar to that of the phorbol ester 12-O-tetradecanoyl-
phorbol-14-acetate (16). Transfection of cells with an acti-
vated ras gene (16) or treatment of cells with TPA (3, 21)
results in induction of genes through the TRE or Ap-1 or
c-jun binding site. In transformed cells, two groups of
transformation-sensitive genes were found: those that were
activated and those that were suppressed. Genes such as
those from simian virus 40, the polyomavirus enhancer, fos,
collagenase, interleukin 2, and transin contain a TRE (3, 16,
18) and are constitutively activated on ras transformation.
Genes which contain a CRE and depend on cAMP for
activation, such as FN, may be suppressed or may remain at
basal levels of activity. It has been demonstrated that
transfection of activated ras genes into cells decreases the
level of FN (34), and we have recently obtained indications
that the rate ofFN biosynthesis and the level of accumulated
FN mRNA varies inversely with the number of activated ras
genes in HT-1080 cells (L. Chandler and S. Bourgeois,
manuscript in preparation).
Determination of the step in the cAMP induction pathway
that is affected by activated members of the ras gene family
may provide insight into one of the cellular functions of ras
and may assist in defining the steps that are involved in
cAMP induction.
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